Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 16, 2022 | Series B | Fr23M | 2 | — | — | Detail |
Nov 6, 2020 | Series B | Fr14M | 2 | — | — | Detail |
May 9, 2018 | Series A | Fr5M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Verve Ventures | — | Series B |
GF Group Holding | — | Series B |
Jaquet Partners | — | Series B |